ViewRay Incorporated recently received U.S. Food and Drug Administration (FDA) 510(k) premarket notification clearance for its MRI-guided radiation therapy system.
The ViewRay system features a combination of radiotherapy delivery and simultaneous MRI for the treatment of cancer. ViewRay’s treatment planning and delivery software received FDA 510(k) premarket notification clearance in 2011.
The ViewRay system provides continuous soft-tissue imaging during treatment so clinicians can see and record precisely where radiation therapy is being delivered as it is being delivered. ViewRay’s patented cancer treatment technology was invented by company founder James F. Dempsey, Ph.D., while he was a member of the radiation oncology faculty at the University of Florida.
The first ViewRay system has been installed at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, where early imaging studies for the system took place. Additional ViewRay partners include UCLA Jonsson Comprehensive Cancer Center and the University of Wisconsin Carbone Cancer Center, where a ViewRay system is currently being installed.